Abstract
Background:
EoL-1 cells have a FIP1L1-PDGFRA fusion gene which causes the transformation of eosinophilic precursor cells into leukemia cells. Recently, we suggested that the induction of differentiation of EoL-1 cells into eosinophils by the HDAC inhibitors apicidin and n-butyrate is due to the continuous inhibition of HDACs. However, neither apicidin nor n-butyrate inhibited the expression of FIP1L1-PDGFRA mRNA, although both these inhibitors suppressed cell proliferation. Therefore, in this study, we analyzed whether the levels of FIP1L1-PDGFRalpha protein and phosphorylated-Stat5 involved in the signaling for the proliferation of EoL-1 cells are attenuated by HDAC inhibitors.
Methods:
EoL-1 cells were incubated in the presence of apicidin, TSA or n-butyrate. FIP1L1-PDGFRalpha and phosphorylated-Stat5 were detected by Western blotting.
Results:
Treatment of EoL-1 cells with apicidin at 100 nM or n-butyrate at 500 microM decreased the levels of FIP1L1-PDGFRalpha protein and phosphorylated-Stat5, while that with trichostatin A at 30 nM did not.
Conclusions:
The decrease in the level of FIP1L1-PDGFRalpha protein caused by apicidin and n-butyrate might be one of the mechanisms by which EoL-1 cells are induced to differentiate into eosinophils by these HDAC inhibitors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Butyrates / pharmacology*
-
Cell Differentiation / drug effects
-
Cell Differentiation / physiology
-
Cell Line, Tumor / cytology
-
Cell Line, Tumor / drug effects
-
Eosinophils / cytology*
-
Gene Expression Regulation, Leukemic / drug effects
-
Histone Deacetylase Inhibitors*
-
Humans
-
Hydroxamic Acids / pharmacology
-
Hypereosinophilic Syndrome / genetics
-
Hypereosinophilic Syndrome / pathology*
-
Neoplasm Proteins / biosynthesis
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / physiology*
-
Oncogene Proteins, Fusion / biosynthesis
-
Oncogene Proteins, Fusion / genetics
-
Oncogene Proteins, Fusion / physiology*
-
Peptides, Cyclic / pharmacology*
-
Phosphorylation / drug effects
-
Protein Processing, Post-Translational / drug effects
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / genetics
-
Receptor, Platelet-Derived Growth Factor alpha / biosynthesis
-
Receptor, Platelet-Derived Growth Factor alpha / genetics
-
Receptor, Platelet-Derived Growth Factor alpha / physiology*
-
STAT5 Transcription Factor / metabolism
-
mRNA Cleavage and Polyadenylation Factors / biosynthesis
-
mRNA Cleavage and Polyadenylation Factors / genetics
-
mRNA Cleavage and Polyadenylation Factors / physiology*
Substances
-
Butyrates
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Neoplasm Proteins
-
Oncogene Proteins, Fusion
-
Peptides, Cyclic
-
RNA, Messenger
-
STAT5 Transcription Factor
-
apicidin
-
mRNA Cleavage and Polyadenylation Factors
-
trichostatin A
-
FIP1L1-PDGFRA fusion protein, human
-
Receptor, Platelet-Derived Growth Factor alpha